Jade Biosciences (JBIO) Corporate presentation summary

Portfolio and funding

• Three Paragon-licensed candidates target autoimmune diseases: JADE101, an anti-APRIL antibody for IgAN; JADE201, an anti-BAFF-R antibody for systemic autoimmune diseases; and JADE301, an anti-IFN-β antibody for dermatomyositis.

• Cash runway extends into Q4 2028; planned milestones include JADE101 Phase 3 initiation in 4Q 2026 and interim Phase 2 data in 2Q 2027, JADE201 interim Phase 1 data in 2027, and JADE301 Phase 1 initiation in 4Q 2026 with interim data in 2H 2027.

JADE101 for IgAN

• The presentation estimates a $20B+ potential U.S. market and 169K+ U.S. patients; 60–75% are estimated to require treatment under international guidelines.

• Phase 1 data showed ~70% IgA reduction sustained for 12 weeks at 700 mg, rapid and sustained free APRIL suppression, and a 24.2-day half-life at the 700 mg induction dose.

• JADE101 was well tolerated across tested doses in 32 healthy volunteers; no severe adverse events, serious adverse events, deaths, or discontinuations due to adverse events were reported.

• A 700 mg induction dose followed by 350 mg maintenance is planned for Q12W or Q8W dosing; the ongoing Phase 2 trial is evaluating both schedules, with interim data anticipated in 2Q 2027.

• The planned Phase 3 trial is expected to start in 4Q 2026, with ~420 participants randomized 2:1 to JADE101 or placebo for Year 1, followed by JADE101 for all participants in Year 2.

JADE201 for autoimmune diseases

• JADE201 combines BAFF-R blockade and enhanced antibody-dependent cellular cytotoxicity; its dual mechanism is designed to deplete B cells and limit BAFF-mediated repopulation.

• In non-human primates, JADE201 showed dose-dependent pharmacokinetics, complete receptor occupancy at doses above 1 mg/kg, and a 5.4-day half-life versus 2.7 days for ianalumab.

• A first-in-human, randomized, placebo-controlled, single-ascending-dose Phase 1 study is underway in adults with rheumatoid arthritis; interim data are expected in 2027.

• Potential indications include lupus nephritis, immune thrombocytopenia, Sjögren's disease, primary membranous nephropathy, ANCA-associated vasculitis, and rheumatoid arthritis.